Pixuvri pixantrone regulatory update

CTI said the Israeli Ministry of Health approved Pixuvri pixantrone as monotherapy to treat multiply relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma (NHL) in patients who have received <=3 prior courses of treatment. Neopharm Group (Petah Tikva, Israel) has rights to commercialize the aza-anthracenedione DNA intercalating agent that inhibits topoisomerase II (TOP2) in Israel. The European Commission approved Pixuvri in 2012. ...